Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 5,852 matching trials from the live ClinicalTrials.gov search.
Filters: "gene therapy" Clear all
Completed Phase 3 Interventional Results available

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

NCT02032875
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

NCT01764477
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
PRI-724
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accelerating Post-exercise Muscle Glycogen Resynthesis in Humans: Impact of Combined Nutrient Intake and Intermittent Pneumatic Compression or Heat Therapy

NCT04371237
View directory record Official record
Conditions
Muscle Recovery, Muscle Soreness, Glycogen Depletion
Interventions
Compression sleeve, Heat therapy, Glycogen-depleting exercise session, Nutrient Intake (beverage), Skeletal muscle biopsy
Device · Other · Procedure
Lead sponsor
PepsiCo Global R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

NCT00326495
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Cetuximab, BAY 43-9006
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

AAVCAGsCD59 for the Treatment of Wet AMD

NCT03585556
View directory record Official record
Conditions
Wet Age-related Macular Degeneration
Interventions
Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral prednisolone
Drug · Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 15, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Engensis (VM202) in the Treatment of Chronic Non-Healing Foot Ulcers

NCT02563522
View directory record Official record
Conditions
Foot Ulcer, Diabetic
Interventions
Engensis (VM202), Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 15, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

Study of Personalized Cancer Therapy to Determine Response and Toxicity

NCT02478931
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Shu Mei Kato
Other
Eligibility
7 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
La Jolla, California • Rancho Mirage, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease

NCT02561702
View directory record Official record
Conditions
Charcot Marie Tooth Disease
Interventions
Placebo, Mexiletine
Other · Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Oct 15, 2026, 4:42 PM EDT
Completed No phase listed Observational

Diagnostic and Screening Study of Genetic Disorders

NCT00006057
View directory record Official record
Conditions
Tay-Sachs Disease, Porphyria, Erythropoietic, Leukodystrophy, Globoid Cell, Metabolism, Inborn Errors
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

NCT07549022
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, MPNST
Interventions
BMS-986504
Drug
Lead sponsor
Ankit Mangla, MD
Other
Eligibility
12 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Active, not recruiting No phase listed Observational

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

NCT00898456
View directory record Official record
Conditions
Leukemia
Interventions
gene expression analysis, molecular genetic technique, polymorphism analysis, protein expression analysis, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 15, 2026, 4:42 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

NCT03220022
View directory record Official record
Conditions
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Filgrastim, Ibrutinib, Laboratory Biomarker Analysis, Pegfilgrastim, Pharmacological Study, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
19
States / cities
La Jolla, California • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Not listed Not applicable Interventional

PHysical Activity and Exercise Outcomes in Huntington's Disease

NCT03344601
View directory record Official record
Conditions
Huntington Disease
Interventions
physical activity
Behavioral
Lead sponsor
Cardiff University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Oral AMXT 1501 Dicaprate in Combination With DFMO

NCT03536728
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Interventions
AMXT1501, DFMO
Drug
Lead sponsor
Aminex Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Austin, Texas • Houston, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 15, 2026, 4:42 PM EDT
Completed No phase listed Observational

Telomere Repair Gene Mutation in Inflammatory Bowel Disease

NCT00353639
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

NCT00514020
View directory record Official record
Conditions
Gastric Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin, gene expression analysis, polymorphism analysis, protein expression analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 15, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

NCT04658303
View directory record Official record
Conditions
Melanoma
Interventions
Pimonidazole
Drug
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

NCT00686842
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
VEGF inhibitor PTC299, gene expression analysis, polymerase chain reaction, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 15, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

NCT04398433
View directory record Official record
Conditions
Respiratory Papillomatosis
Interventions
INO-3107, CELLECTRA® 2000
Drug · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Not yet recruiting Early Phase 1 Interventional

A Pilot Study to Examine the Efficacy and Tolerability of Sirolimus on Epidermal Nevi Lesions in Patients 6 Years Old and Above.

NCT07813533
View directory record Official record
Conditions
Epidermal Nevi
Interventions
sirolimus topical gel 0.2%
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations

NCT00774176
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Temple University
Other
Eligibility
40 Years to 80 Years
Enrollment
1,066 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
3
States / cities
Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 15, 2026, 4:42 PM EDT
Terminated Phase 1 Interventional

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

NCT01164917
View directory record Official record
Conditions
Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus
Interventions
AMG811, AMG811 Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Santa Monica, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 15, 2026, 4:42 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

NCT07517068
View directory record Official record
Conditions
Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response
Interventions
ACETAZOLAMIDE oral capsule, Placebo Arm
Drug · Device
Lead sponsor
University of California, Riverside
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 15, 2026, 4:42 PM EDT
Completed No phase listed Observational

Radiation Biodosimetry in Children Undergoing Total Body Irradiation

NCT01337648
View directory record Official record
Conditions
Total-body Irradiation, Hematopoietic Stem Cell Transplant
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 15, 2026, 4:42 PM EDT